CHMP Knocks Back TLC’s Doxorubicin Hybrid
Executive Summary
As the CHMP refuses to recommend granting approval for TLC’s doxorubicin hybrid, the committee within the EMA has given the nod to Teva’s Ajovy monoclonal antibody migraine remedy as well as two small-molecule generics from Krka.
You may also be interested in...
Accord Sees Two Hybrids Endorsed By EU’s CHMP
The latest CHMP meeting has seen the EMA committee issue a positive opinion on two Accord hybrid medicines, Zolsketil (doxorubicin) and Camcevi (leuprorelin), at the same time as SERB’s generic amifampridine tablets were also endorsed.
CHMP Maintains Refusal Of TLC's Doxorubicin
The CHMP has confirmed its negative opinion on TLC Biopharmaceuticals’ doxorubicin hybrid. Meanwhile, Accord has received two posaconazole approvals, Zentiva has withdrawn an application for ambrisentan, and the EMA has launched a review of methocarbamol/paracetamol medicines.
TLC Seeks A Second Opinion On Doxolipad
After the CHMP previously refused to recommend granting approval for TLC’s doxorubicin hybrid, the firm has asked the committee within the EMA to revisit its opinion.